Lakewood-Amedex Biotherapeutics (LABT) Q2 2026 earnings summary

Executive summary

• Completed $7.5 million Series C Convertible Preferred Stock financing, raising $6.8 million net proceeds and strengthening liquidity.

• Listed common stock on Nasdaq Capital Market, simplifying capital structure via conversion of preferred stock and convertible debt.

• Focus shifted to advancing clinical development, particularly the planned Phase 2a study for lead product Nu-3.

Financial highlights

• Net loss was $3.77 million for Q2 2026, compared to $0.66 million in Q2 2025; net loss for the six months was $4.70 million, up from $1.20 million year-over-year.

• Operating expenses rose to $3.79 million in Q2 2026 from $0.64 million in Q2 2025, driven by higher R&D and G&A costs.

• Cash, cash equivalents, and investments totaled $4.6 million at June 30, 2026, up from $0.24 million at year-end 2025.

• Working capital improved to $4.2 million at June 30, 2026, from a deficit of $2.1 million at December 31, 2025.

Outlook and guidance

• Current liquidity expected to fund operations into Q1 2027; additional capital will be required to complete clinical development and commercialization.

• Management plans to pursue further equity or debt financing, partnerships, or grants.